Nanobody Identification Against SARS-CoV-2
- An international research team led by the University of Bonn (Germany) has identified novel antibody fragments (Nanobodies) against SARS-Cov-2 (SARS-CoV-2) virus.
- It is known that SARS-CoV-2 is a virus caused by the coronavirus
Nanobody against SARS-CoV-2:
- Injection of superficial proteins of the corona virus into an alpaca and a llama produces not only an antibody targeted to the virus by their immune system, but also can work in a simple antibody variant that forms the basis of the Nanobody.
- They also combined Nanobodies into potentially effective molecules that simultaneously attack different parts of the virus. This process will help prevent microbes from producing the effect of antibodies through mutation.
- Nanobodies take the form of a structural change before the virus encounters its target cell, which is an unpredictable and novel type of function. Structural changes are likely to remain constant. Therefore, in this stage, the virus is not able to nourish and infect the cells.
Antibodies:
- An immune system is an important tool against antibody infection.
- These bind to structures on the surface of bacteria or viruses and prevent their replication from occurring.
- This is why the important step in the fight against any disease is to produce large amounts of effective antibodies and inject them into patients.
- Although producing antibodies is often a difficult and relatively long-term process; therefore it is not considered suitable for widespread use.
Nanobodies:
- Nanobodies are fragments of antibodies that are so simple that they can be generated by bacteria or yeast, a relatively inexpensive function.
- Nanobodies are a type of single-domain antibody, also known as VHH antibodies.
- They are often seen as an alternative to traditional antibodies and are different from antibodies in both production and use, which affects their suitability.
Source: Indian Express
